Tissue-specific activity of heterologous viral promoters in primary rat hepatocytes and Hep G2 cells

Authors

  • Fang Xian-Jun,

    1. Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada
    2. Tanox Biosystems, Inc, Houston, Texas 77025
    Search for more papers by this author
  • Armand Keating,

    1. Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada
    2. Tanox Biosystems, Inc, Houston, Texas 77025
    Search for more papers by this author
  • Jean de Villiers,

    1. Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada
    2. Tanox Biosystems, Inc, Houston, Texas 77025
    Search for more papers by this author
  • Dr. Morris Sherman

    Corresponding author
    1. Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada
    2. Tanox Biosystems, Inc, Houston, Texas 77025
    • Toronto General Hospital, en9-225, 200 Elizabeth St., Toronto, Ontario M5G 2C4, Canada
    Search for more papers by this author

Abstract

In preparation for studies using gene transfer, we have identified transcriptional control elements which are active in primary rat hepatocytes. We used plasmids which were constructed so that the promoter or enhancer of interest initiated transcription of the bacterial chloramphenicol acetyltransferase (CAT) gene. Plasmids were introduced into primary rat hepatocytes in culture, into Hep G2 cells and other human and animal cell lines and into bone marrow stromal cells, and CAT activity was assayed after 48 hr.

In primary rat hepatocytes, the highest CAT activity was obtained with plasmids carrying the Rous sarcoma virus long terminal repeat (pRSVCAT), or the SV40 early region promoter and enhancer (pSV2CAT). Hepatocytes carrying the murine cytomegalovirus immediate early promoter (pUCRNmCMVX/HCAT) also had appreciable CAT activity. No CAT activity was detected in rat hepatocytes carrying pSVOCAT (a promoterless construct), pUCRNtKCAT (herpes simplex thymidine kinase gene promoter), pLPVCAT (lymphocytotrophic papovavirus promoter) and pHBV1CAT (hepatitis B virus enhancer and core gene promoter). Therefore, for future studies of gene transfer in primary rat hepatocytes, the Rous sarcoma virus long terminal repeat or the SV40 early region promoter and enhancer can be effectively used to drive gene expression.

Hep G2 cells carrying pHBV1CAT had high CAT activity. Hep G2 cells carrying pHBV2CAT (similar to pHBV1CAT, but with the hepatitis B virus sequences in reverse orientation with respect to the CAT sequences) and pHBV3CAT (similar to pHBV2CAT, but hepatitis B virus sequences are separated from the CAT sequences by about 700 bases) also expressed CAT activity, but not as strongly as with pHBV1CAT. The hepatitis B virus enhancer and core gene promoter were also active in human nonliver cell lines but were virtually inactive in nonhuman cell lines.

Ancillary